The cells are distributed for research purposes only. The Memorial Sloan-Kettering Cancer Center releases the line subject to the following: 1.) The cells or their products must not be distributed to third parties. Commercial interests are the exclusive property of Memorial Sloan-Kettering Cancer Center. 2.) Any proposed commercial use of these cells must first be negotiated with The Director, Office of Industrial Affairs, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021; phone (212) 639-6181; FAX (212) 717-3439.

epidermal growth factor (EGF); transforming growth factor beta (type 1 and type 2)

Blood Type B, Rh+; HLA A2, A3, Bw16, Bw47

The stemline chromosome number is hypotriploid with the modal number of 56 chromosomes per cell and the 2S component occurring at 13.2%. Over two-thirds of the chromosome complement consisted of structurally rearranged chromosomes.
Most marker chromosomes had complex rearrangements. The origin of the segments composing these markers could not be identified. Of the identifiable markers, 6p+/q+, 7p+, 11p+, and 12p+ occasionally were present at 2 copies per cell.
The Y chromosome was not detected in the QM stained preparation.

11 years

Caucasian

ATCC complete growth medium: The base medium for this cell line is ATCC-formulated McCoys 5a Medium Modified, Catalog No. 30-2007. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 15%.
Temperature: 37.0C
Atmosphere: air, 95%; carbon dioxide (CO2), 5%

Culture medium, 95%; DMSO, 5%

21441: Banerjee C , et al. An AML-1 consensus sequence binds an osteoblast-specific complex and transcriptionally activates the osteoclacin gene. Proc. Natl. Acad. Sci. USA 93: 4968-4973, 1996. PubMed:
21869: Fogh J, editor. Human tumor cells in vitro. 93: New York: Plenum Press; 1975, pp. 115-159.
22536: Fogh J , et al. Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J. Natl. Cancer Inst. 58: 209-214, 1977. PubMed: 833871
22539: Fogh J , et al. One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J. Natl. Cancer Inst. 59: 221-226, 1977. PubMed: 327080
23014: Takeuchi Y , et al. Relationship between actions of transforming growth factor (TGF)-beta and cell surface expression of its receptors in clonal osteoblastic cells. J. Cell. Physiol. 162: 315-321, 1995. PubMed:
23015: Zhang W , et al. EGF-mediated phosphorylation of extracellular signal-regulated kinases in osteoblastic cells. J. Cell. Physiol. 162: 348-358, 1995. PubMed:
23226: Pollack MS , et al. HLA-A, B, C and DR alloantigen expression on forty-six cultured human tumor cell lines. J. Natl. Cancer Inst. 66: 1003-1012, 1981. PubMed:
32279: Schar BK , et al. Simultaneous detection of all four alkaline phosphatase isoenzymes in human germ cell tumors using reverse transcription-PCR. Cancer Res. 57: 3841-3846, 1997. PubMed:
32462: Morris GF , et al. Transcriptional activation of the human proliferating-cell nuclear antigen promoter by p53. Proc. Natl. Acad. Sci. USA 93: 895-899, 1996. PubMed:
32556: Werner H , et al. Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene. Proc. Natl. Acad. Sci. USA 93: 8318-8323, 1996. PubMed:
32900: Wang X , et al. Variabilin, a novel RGD-contining antagonist of glycoprotein IIb-IIIa and platelet aggregation inhibitor from the gard tick Dermacentor variabilis. J. Biol. Chem. 271: 17785-17790, 1996. PubMed:
33153: Karnieli E , et al. The IGF-1 receptor gene promoter is a molecular target for the Ewings Sarcoma=Wilms Tumor 1 fusion protein. J. Biol. Chem. 271: 19304-19309, 1996. PubMed: